Ovid Therapeutics (OVID) Free Cash Flow (2016 - 2026)
Ovid Therapeutics' (OVID) quarterly Free Cash Flow came in at -$13.9 million in Q1 2026, down 35.2% YoY from -$21.5 million in Q1 2025, and down 33.98% on a QoQ basis from -$10.4 million in Q4 2025.
Ovid Therapeutics (OVID) Free Cash Flow (2016 - 2026) Analysis & Trends
Ovid Therapeutics (OVID) has 11 years of Free Cash Flow data on file, last reported at -$13.9 million in Q1 2026.
- Quarterly Free Cash Flow fell 35.2% year-over-year to -$13.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$41.9 million (up 15.52% YoY) and the FY2025 annual result came in at -$38.3 million, up 31.66% from the prior year.
- Free Cash Flow fell to -$13.9 million in Q1 2026, from -$10.4 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$4.8 million in Q2 2025 to a low of -$20.1 million in Q1 2022.
- A 5-year average of -$12.4 million and a median of -$12.1 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow sank 112.5% — and 2025, when it jumped 66.42%.
- Tracing OVID's Free Cash Flow over 5 years: stood at -$9.3 million in 2022, then dropped by 28.89% to -$12.0 million in 2023, then rose by 16.68% to -$10.0 million in 2024, then decreased by 3.93% to -$10.4 million in 2025, then tumbled by 33.98% to -$13.9 million in 2026.
- The last three Free Cash Flow figures came in at -$13.9 million (Q1 2026), -$10.4 million (Q4 2025), and -$12.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - | -13.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.90 Mn |
| Mar 31, 2026 | -13.90 Mn |
| Dec 31, 2025 | -10.37 Mn |
| Dec 31, 2025 | -10.37 Mn |
| Sep 30, 2025 | -12.83 Mn |
| Sep 30, 2025 | -12.83 Mn |
| Jun 30, 2025 | -4.82 Mn |
| Jun 30, 2025 | -4.82 Mn |
| Mar 31, 2025 | -10.28 Mn |
| Mar 31, 2025 | -10.28 Mn |
| Dec 31, 2024 | -9.98 Mn |
| Dec 31, 2024 | -9.98 Mn |
| Sep 30, 2024 | -15.01 Mn |
| Sep 30, 2024 | -15.01 Mn |
| Jun 30, 2024 | -14.35 Mn |
| Jun 30, 2024 | -14.35 Mn |
| Mar 31, 2024 | -16.71 Mn |
| Mar 31, 2024 | -16.71 Mn |
| Dec 31, 2023 | -11.98 Mn |
| Dec 31, 2023 | -11.98 Mn |